Group 1 - The stock of Aonlikang is approaching a limit down, indicating significant selling pressure [1] - Several pharmaceutical companies, including Nanjing New Pharmaceutical, Huason Pharmaceutical, Yuekang Pharmaceutical, Chenxin Pharmaceutical, Guizhou Bailing, and Shutaishen, have all experienced declines exceeding 6% [1]

二、对公司的影响 重庆华森制药股份有限公司 关于公司缴纳税款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）近期对纳税义务履行情 况开展了自查，现将有关情况公告如下： 一、基本情况 公司在日常税务合规自查过程中，对公司可转换公司债券相关财税处理进 行了专项复核，经全面自查确认，因可转债利息费用的税会处理差异，需补缴 企业所得税 7,174,740.43 元，企业所得税滞纳金 2,844,784.58 元。 截至本公告披露日，公司已将上述税款及滞纳金缴纳完毕，主管税务部门 未对该事项给予处罚。 证券代码：002907 证券简称：华森制药 公告编号：2025-062 根据《企业会计准则第 28 号—会计政策、会计估计变更和差错更正》相关 规定，上述事项不属于前期会计差错，不涉及前期财务数据追溯调整。公司补 缴上述税款及滞纳金将计入 2025 年当期损益，预计将影响公司 2025 年度归属 于上市公司股东的净利润 10,019,525.01 元，最终财务数据以 2025 年度经审计 的财务报表为准。本事项不会对公司 ...

华森制药公告称，公司在税务合规自查中发现，因可转债利息费用的税会处理差异，需补缴企业所得税 717.47万元，企业所得税滞纳金284.48万元。目前公司已完成税款及滞纳金缴纳。该事项将影响公司 2025年度归属于上市公司股东的净利润1001.95万元，最终数据以审计结果为准。 ...

Market Performance - The two markets opened lower on Friday, with the Shanghai Composite Index closing at 3559.95 points, down 0.37%, and the Shenzhen Component down 0.17% [1] - The total trading volume was 15,984 billion, a significant decrease of 3,377 billion (-17.44%) compared to Thursday [1] - Over 80% of industry sectors saw gains, with warehousing logistics, construction decoration, software, paper printing, and ecological environment sectors leading the rise [1] Industry Highlights - The Chinese medicine sector experienced a significant surge, with Weikang Pharmaceutical hitting the 20% daily limit, alongside other companies like Tianmu Pharmaceutical and Guizhou Bailin also reaching the limit [1] - The photovoltaic sector also performed well, with Jiejia Weichuang and Shuangliang Energy both hitting the daily limit [1] Technical Analysis - The three major indices showed a volume contraction and closed with long upper shadows, indicating a potential reversal after five consecutive weeks of gains [2] - The Shanghai Composite, Shenzhen Component, and ChiNext Index fell by 0.94%, 1.58%, and 0.74% respectively for the week, with total trading volume at 8.93 trillion, down 1.76% from the previous week [2] Investment Strategy - Companies are advised to reduce positions in high-flying stocks that have seen significant gains, while looking to invest in undervalued small and mid-cap growth stocks that have shown strong performance in Q1 and exceeded expectations in H1 [2] - There is a recommendation to allocate some resources towards brokerage stocks in anticipation of the upcoming half-year and third-quarter earnings reports [2]

Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing significant opportunities due to favorable policies and market developments, with a notable surge in stock performance among TCM companies [6][9]. Market Performance - On August 1, the A-share market saw a slight decline, with the Shanghai Composite Index down 0.37%, Shenzhen Component Index down 0.17%, and ChiNext Index down 0.24%. However, over 3,300 stocks rose in the market [1][2]. - The TCM sector led the market with a substantial increase, as evidenced by the 1.78% rise in the Shenwan TCM Index, with several companies, including Weikang Pharmaceutical and Tianmu Pharmaceutical, hitting the daily limit [5][6]. Policy and Industry Developments - The establishment of the Yangtze River Delta TCM Concept Verification and Achievement Transformation Center in Shanghai aims to enhance the commercialization of TCM research and development [6]. - The State Council's 2025 directive emphasizes the protection and utilization of TCM resources, indicating a supportive regulatory environment for the industry [6]. Company Performance - Notable TCM companies reported significant profit growth in the first half of 2025. For instance, Darentang's net profit is expected to reach between 18.4 billion to 20 billion yuan, marking a year-on-year increase of 180% to 204% [9][11]. - Jilin Aodong anticipates a net profit of approximately 12.36 billion to 12.9 billion yuan, reflecting a year-on-year growth of 130% to 140% [9][11]. - Tianmu Pharmaceutical successfully turned a profit during the reporting period, driven by enhanced sales in pharmaceuticals and medical devices [10]. Investment Insights - Analysts suggest that the TCM sector is poised for growth, driven by innovative products and strong brand recognition, particularly in high-value markets [7][8]. - The focus on stable cash flow to support R&D expenditures is expected to be a key strategy for TCM companies moving forward [7].

Core Viewpoint - On the first trading day of August, China's A-shares experienced a correction with major indices declining, but the traditional Chinese medicine sector showed resilience, rising significantly [1] Market Performance - The traditional Chinese medicine sector increased by 3.39%, leading all industry sectors in A-shares [1] - Notable individual stocks included Weikang Pharmaceutical, Tianmu Pharmaceutical, Xintian Pharmaceutical, and Huason Pharmaceutical, with Weikang Pharmaceutical achieving approximately a 20% increase [1] - The Shanghai Composite Index closed at 3559 points, down 0.37%; the Shenzhen Component Index closed at 10991 points, down 0.17%; and the ChiNext Index closed at 2322 points, down 0.24% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 15,984 billion RMB, a decrease of about 3,377 billion RMB compared to the previous trading day [1] Industry Developments - The Long Triangle Traditional Chinese Medicine Concept Verification and Achievement Transformation Center was officially launched, aiming to address early bottlenecks in the transformation of traditional Chinese medicine achievements [1] Analyst Insights - According to Guo Yiming, Director of Investment Advisory at Jifeng Investment Consulting, the decline in A-shares on August 1 was primarily a technical adjustment due to the indices reaching a phase high, coupled with profit-taking [1] - The overall outlook remains positive, with the fundamental recovery of the Chinese economy, improved market liquidity, and supportive policies indicating limited downward space for the indices in the future [1]

Market Performance - As of August 1, the pharmaceutical e-commerce sector rose by 1.51%, ranking 9th among concept sectors, with 114 stocks increasing in value [1] - Notable gainers included Weikang Pharmaceutical with a 20% limit-up, and New Tian Pharmaceutical, Huason Pharmaceutical, and Qizheng Tibetan Medicine also hitting the limit-up [1] - The top performers in the sector were Shenzhou Pharmaceutical, Dajia Weikang, and Zhongsheng Pharmaceutical, with increases of 23.15%, 8.87%, and 7.49% respectively [1] Capital Flow - The pharmaceutical e-commerce sector saw a net inflow of 899 million yuan from main funds, with 84 stocks receiving net inflows [2] - Leading the net inflow was Zhongsheng Pharmaceutical with 533 million yuan, followed by Huason Pharmaceutical, Taiji Group, and New Tian Pharmaceutical with net inflows of 111 million yuan, 98 million yuan, and 82 million yuan respectively [2] Stock Performance - New Tian Pharmaceutical, Weikang Pharmaceutical, and Kefu Medical had the highest net inflow ratios at 43.47%, 16.51%, and 15.73% respectively [3] - The top stocks in the pharmaceutical e-commerce sector based on net inflow included Zhongsheng Pharmaceutical, Huason Pharmaceutical, and Taiji Group, with respective daily increases of 7.49%, 10.03%, and 4.09% [3] Decliners - The stocks with the largest declines included Erkang Pharmaceutical, Kangzhi Pharmaceutical, and Laimei Pharmaceutical, which fell by 9.59%, 7.15%, and 5.81% respectively [1][10] - The overall market showed mixed performance with some sectors experiencing significant losses while others gained traction [10]

证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交2.42亿元，其中，买入成交额为1.64亿 元，卖出成交额为7869.44万元，合计净买入8508.37万元。 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即买一，合计净买入4635.90万元，深股 通为第四大买入营业部及第一大卖出营业部，买入金额为2343.99万元，卖出金额为4536.73万元，合计 净卖出2192.74万元。 资金流向方面，今日该股主力资金净流入1.11亿元，其中，特大单净流入1.00亿元，大单资金净流入 1077.64万元。近5日主力资金净流入1.55亿元。（数据宝） 华森制药今日涨停，全天换手率12.37%，成交额7.64亿元，振幅8.47%。龙虎榜数据显示，机构净买入 4635.90万元，深股通净卖出2192.74万元，营业部席位合计净买入6065.21万元。 深交所公开信息显示，当日该股因日涨幅偏离值达9.98%上榜，机构专用席位净买入4635.90万元，深股 通净卖出2192.74万元。 华森制药8月1日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- ...

（文章来源：每日经济新闻） 每经AI快讯，8月1日，午后中药板块持续逆势拉升，天目药业、华森制药涨停，生物谷一度触及30%涨 停，新光药业、大唐药业涨超10%，亚宝药业、沃华医药、陇神戎发、粤万年青等跟涨。 ...

Group 1 - The A-share traditional Chinese medicine sector is experiencing a significant upward trend, with companies like Tianmu Pharmaceutical and Huasen Pharmaceutical hitting the daily limit increase [1] - Biotech Valley reached a peak of 30cm limit increase, indicating strong market interest and investor confidence [1] - Other companies such as New Light Pharmaceutical and Datang Pharmaceutical saw increases of over 10%, reflecting a broader positive movement in the sector [1] Group 2 - Additional companies including Yabao Pharmaceutical, Wohua Pharmaceutical, Longshen Rongfa, and Guangdong Wannianqing also showed gains, contributing to the overall bullish sentiment in the traditional Chinese medicine market [1]